Evolution Biotechnologies selected to participate in InvestEU Matchmaking event 2019 - Evolution Biotechnologies
post-template-default,single,single-post,postid-9354,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Evolution Biotechnologies selected to participate in InvestEU Matchmaking event 2019

Bedford, UK, February 23rd, 2019

Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today reports that as a holder of the European Seal of Excellence for its work on house dust mite control, it has been selected to participate in the InvestEU Matchmaking event, to be held in Brussels, Belgium, on March 19th, 2019.

The event involves discussions on sustainable finance and innovation, the Investment Plan for Europe, the InvestEU programme, and the Horizon 2020 and Horizon Europe programmes. After the discussions, attendees are invited to attend a dedicated matchmaking session with a panel of 50 selected investors.

Dr. David Harper, Evolution’s CEO, said “this is an excellent opportunity to receive an update on these programs and to interact with an extensive group of interested investors. This builds on our receipt of the Seal of Excellence for our work on house dust mite control and on our recently allowed European patent protecting this work”.

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027 and US company 6050853) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the development of a novel, self-amplifying biological control for the house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document and the video interviewed referenced herein contain certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.com

Website: www.evolutionbiotech.com

No Comments

Sorry, the comment form is closed at this time.